Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: chronic myelogenous leukaemia therapeutics - Novartis/SGX Pharmaceuticals

Next Previous
X
Search
Drug Profile

Research programme: chronic myelogenous leukaemia therapeutics - Novartis/SGX Pharmaceuticals

Alternative Names: 7-Azaindole inhibitors; SGX 393; SGX 70393; SGX-70430

Latest Information Update: 19 Jul 2010

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SGX Pharmaceuticals
  • Developer Novartis; SGX Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic myeloid leukaemia

Most Recent Events

  • 20 Aug 2008 SGX Pharmaceuticals has been acquired by Eli Lilly and Company
  • 30 Jun 2008 SGX Pharmaceuticals files an IND application with the US FDA for SGX 393
  • 11 Dec 2007 Pharmacodynamics data from a preclinical trial presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top